Cullen L Schmid

Title: Cullen L. Schmid: Innovator in Opioid Modulation

Introduction

Cullen L. Schmid is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of opioid research, particularly in developing novel compounds that aim to improve pain management while minimizing side effects.

Latest Patents

Cullen L. Schmid holds 2 patents, with his latest inventions focusing on the synthesis of 20-nor-salvinorin A and signaling-biased mu opioid receptor agonists. The first patent, titled "Synthesis of 20-nor-salvinorin A," presents an analog of the kappa-opioid agonist salvinorin A. This compound is an active kappa-opioid modulator that can be utilized for treating various medical conditions, including pain, pruritis, depression, and inflammation. Notably, 20-nor-salvinorin A is designed to be less addictive compared to traditional mu-opioid receptor agonists and demonstrates greater stability in vivo than its parent compound. The invention also includes synthetic intermediates and procedures for preparing 20-nor-salvinorin A. The second patent, "Signaling-biased mu opioid receptor agonists," introduces opioid receptor agonists that serve as analgesic agents while promoting reduced side effects compared to morphine. These side effects may include constipation, respiratory depression, tolerance, dependence, and more.

Career Highlights

Cullen L. Schmid is affiliated with The Scripps Research Institute, where he continues to advance his research in opioid modulation. His work is pivotal in addressing the challenges associated with opioid use in medical treatments.

Collaborations

Cullen has collaborated with esteemed colleagues, including Laura Bohn and Ryan Shenvi, to further enhance the impact of his research in the field.

Conclusion

Cullen L. Schmid's innovative work in opioid modulation represents a significant advancement in pain management therapies. His contributions are essential in the ongoing effort to develop safer and more effective treatments for patients.